Inspire Medical Systems, Inc. (NYSE:INSP) Shares Bought by WINTON GROUP Ltd

WINTON GROUP Ltd boosted its stake in shares of Inspire Medical Systems, Inc. (NYSE:INSP) by 15.6% in the fourth quarter, HoldingsChannel.com reports. The fund owned 5,977 shares of the company’s stock after purchasing an additional 806 shares during the period. WINTON GROUP Ltd’s holdings in Inspire Medical Systems were worth $1,108,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Mutual of America Capital Management LLC lifted its position in Inspire Medical Systems by 1.2% during the fourth quarter. Mutual of America Capital Management LLC now owns 4,540 shares of the company’s stock worth $842,000 after buying an additional 55 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in shares of Inspire Medical Systems by 1.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 7,879 shares of the company’s stock valued at $1,461,000 after buying an additional 79 shares in the last quarter. Xponance Inc. grew its position in Inspire Medical Systems by 2.2% in the 4th quarter. Xponance Inc. now owns 3,824 shares of the company’s stock valued at $709,000 after acquiring an additional 82 shares in the last quarter. Harbour Investments Inc. grew its holdings in shares of Inspire Medical Systems by 101.0% in the fourth quarter. Harbour Investments Inc. now owns 197 shares of the company’s stock valued at $37,000 after purchasing an additional 99 shares in the last quarter. Finally, Nisa Investment Advisors LLC grew its stake in shares of Inspire Medical Systems by 37.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 368 shares of the company’s stock worth $68,000 after acquiring an additional 100 shares in the last quarter. 94.91% of the stock is owned by hedge funds and other institutional investors.

Inspire Medical Systems Price Performance

INSP opened at $156.91 on Friday. Inspire Medical Systems, Inc. has a 1-year low of $123.00 and a 1-year high of $257.40. The stock has a market cap of $4.67 billion, a P/E ratio of 90.70, a P/E/G ratio of 2.86 and a beta of 1.48. The stock’s 50 day simple moving average is $179.14 and its 200 day simple moving average is $190.19.

Inspire Medical Systems (NYSE:INSP) last posted its earnings results on Monday, February 10th. The company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.41. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%. Research analysts expect that Inspire Medical Systems, Inc. will post 2.16 EPS for the current fiscal year.

Insider Activity

In related news, CTO John Rondoni sold 583 shares of the company’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $170.49, for a total value of $99,395.67. Following the completion of the transaction, the chief technology officer now directly owns 10,424 shares in the company, valued at approximately $1,777,187.76. This represents a 5.30 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Randy Ban sold 25,584 shares of the stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $183.50, for a total transaction of $4,694,664.00. Following the transaction, the insider now owns 7,259 shares in the company, valued at approximately $1,332,026.50. The trade was a 77.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 26,225 shares of company stock worth $4,806,530 over the last three months. 4.10% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Stifel Nicolaus cut their target price on shares of Inspire Medical Systems from $200.00 to $190.00 and set a “hold” rating on the stock in a research note on Tuesday, January 21st. KeyCorp reaffirmed an “overweight” rating and set a $234.00 price objective (down previously from $236.00) on shares of Inspire Medical Systems in a report on Friday, January 24th. Robert W. Baird cut their target price on shares of Inspire Medical Systems from $252.00 to $248.00 and set an “outperform” rating on the stock in a report on Tuesday, February 11th. Morgan Stanley dropped their price target on Inspire Medical Systems from $230.00 to $220.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 11th. Finally, Truist Financial dropped their price objective on shares of Inspire Medical Systems from $250.00 to $235.00 and set a “buy” rating on the stock in a research note on Tuesday, February 11th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $226.70.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.